Grant✓ Small businesses may apply
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
$300,000
Program funding
$5,900,000
- Opportunity #
- RFA-CA-27-002
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.394
- Status
- posted
- Posted
- Jun 3, 2026
- Closes
- Nov 10, 2026
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •County governments
- •Public housing authorities/Indian housing authorities
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Special district governments
- •City or township governments
- •Small businesses
- •Native American tribal governments (Federally recognized)
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •State governments
- •Public and State controlled institutions of higher education
- •For profit organizations other than small businesses
- •Private institutions of higher education
- •Independent school districts
- •Native American tribal organizations (other than Federally recognized tribal governments)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Contact
National Institutes of Health · NCI-IMAT@nih.gov